PanTarg is developing next-generation antibody-drug conjugates (ADCs) to treat some of the most aggressive cancers. Our lead program focuses on pancreatic cancer, one of the deadliest tumor types with very limited treatment options, while our approach holds broad pan-cancer potential.

Our ADCs are designed with a dual-attack mechanism that targets both cancer cells and the tumor-supporting stroma. By dismantling the protective shield around tumors, we aim to improve treatment penetration, overcome resistance, and enhance therapeutic outcomes.

PanTarg is a Danish biotech spin-out from Rigshospitalet and the University of Copenhagen, founded by researchers with extensive experience in ADC development. We are advancing a proprietary uPAR-targeted ADC through preclinical development with the ambition of delivering a transformative therapy to patients in need.

PanTarg’s therapies are currently in development and are not yet available to patients.

PanTarg

Org chart

Teams

Offices